DNA Methylation Biomarkers for Cervical Cancer Screening

NCT ID: NCT02605941

Last Updated: 2015-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Intraepithelial Neoplasia Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with age ≥20 and sexual experience
* Agree to sign ICF

Exclusion Criteria

* women had received Hysterectomy
* women had destructive therapy for cervical lesions in 6 months, for examples: conization, Laser or cryotherapy, chemotherapy, and radiation therapy
* Women are at pregnancy or had baby delivery in 6 weeks
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mackay Memorial Hospital

OTHER

Sponsor Role collaborator

Li Shin Hospital

OTHER

Sponsor Role collaborator

Chang Gung Memorial Hospital

OTHER

Sponsor Role collaborator

iStat Biomedical CO., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yuh-cheng Yang, MD

Role: STUDY_CHAIR

Mackay Memorial Hospital

Shih-chu Ho, MD

Role: PRINCIPAL_INVESTIGATOR

Li Shin Hospital

Ting-Chang Chang, MD., MPH.

Role: PRINCIPAL_INVESTIGATOR

Chang Gung Memorial Hospital

Chih-Long Chang, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Mackay Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mackay Memorial Hospital, Linkou Chang Gung Memorial Hospital, Lin-Shin Medical Corporation Lin-Shin Hosptial

Taipei, Taoyuan, and Taichung, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chien-Ping Hung

Role: CONTACT

+886-2-2696-3518 ext. 15

Hsiu-yuan Tsao

Role: CONTACT

+886-2-2696-3518 ext. 14

References

Explore related publications, articles, or registry entries linked to this study.

Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):114-23. doi: 10.1158/1055-9965.EPI-05-0323.

Reference Type BACKGROUND
PMID: 16434596 (View on PubMed)

Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008 Jul 1;123(1):161-7. doi: 10.1002/ijc.23519.

Reference Type BACKGROUND
PMID: 18398837 (View on PubMed)

Huang TH, Lai HC, Liu HW, Lin CJ, Wang KH, Ding DC, Chu TY. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer. 2010 May;20(4):513-9. doi: 10.1111/IGC.0b013e3181c7fe6e.

Reference Type BACKGROUND
PMID: 20442585 (View on PubMed)

Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, Su PH, Liu YL, Yu MH. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer. 2010 Sep 15;116(18):4266-74. doi: 10.1002/cncr.25252.

Reference Type BACKGROUND
PMID: 20564139 (View on PubMed)

Chao TK, Ke FY, Liao YP, Wang HC, Yu CP, Lai HC. Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of paired boxed gene 1 (PAX1). Diagn Cytopathol. 2013 Jan;41(1):41-6. doi: 10.1002/dc.21758. Epub 2011 Jun 27.

Reference Type BACKGROUND
PMID: 21710649 (View on PubMed)

Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer. 2001 Feb 25;93(1):8-15.

Reference Type BACKGROUND
PMID: 11241260 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

epigene-13151

Identifier Type: -

Identifier Source: org_study_id